Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ ...Learn More

Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. Introducing polyethylene glycol (PEG) ...Learn More

SAN DIEGO, CA – April 29, 2025 – Biopharma PEG Scientific Inc., a leading provider of high-quality polyethylene glycol (PEG) derivatives, today announced its participation in TIDES USA 2025, taking place from May 19 - 22, 2025, at the Manchester Grand Hyatt San Diego. ...Learn More

Watertown, MA – March 24, 2025 – Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, highlights its innovative product DSPE-PEG-Mannose, an advanced biomedical polymer with significant potential in drug delivery, tumor-targeted therapy, ...Learn More

Watertown, MA, July 22, 2024 – Biopharma PEG, a top supplier of PEG derivatives, is excited to introduce its new line of monodispersed PEGs. These specially sized polymers are designed to improve the stability and delivery of proteins and peptides in drugs. They are essential ...Learn More